Efgartigimod shows potential as maintenance therapy for iTTP in pilot study
A pilot study indicates that efgartigimod may effectively increase ADAMTS13 activity in patients with iTTP, potentially preventing relapses.
Asset / Drug
Drug and asset intelligence for rituximab with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.